Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants

Trial Profile

An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Talditercept alfa (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb; Roche
  • Most Recent Events

    • 29 Jun 2018 Status changed from recruiting to completed.
    • 02 Aug 2017 Planned End Date changed from 1 Sep 2017 to 30 Sep 2017.
    • 02 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top